Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:PROK

ProKidney Q3 2026 Earnings Date & Estimates

ProKidney logo
$1.33 -0.13 (-8.59%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$1.32 -0.02 (-1.13%)
As of 10/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProKidney is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for November 10, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ProKidney in Q3 2026

ProKidney is expected to post earnings of -$0.12 per share on revenue of $0.13 million. In the same quarter a year earlier ProKidney reported -$0.12 per share on revenue of $0.22 million. ProKidney last reported on August 10, 2026, posting -$0.15 per share and missing the -$0.14 consensus estimate. ProKidney has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.12
Expected Revenue
$0.13 million
Prior-Year EPS
-$0.12
Prior-Year Revenue
$0.22 million
Expected Revenue Growth
-42.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.15 (Missed by -$0.01)
Last Quarter Revenue
$0.15 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

ProKidney Q3 2026 Earnings FAQ

ProKidney (NASDAQ:PROK) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

ProKidney's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ProKidney to post earnings of -$0.12 per share for Q3 2026.

The consensus revenue estimate for ProKidney is $0.13 million for Q3 2026.

ProKidney Earnings Headlines

ProKidney Corp. (PROK) Stock Earnings Call Transcripts - Yahoo Finance
October 15 at 12:51 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PROK/earnings-calls/
ProKidney (NASDAQ:PROK) Shares Down 6% - Here's Why
October 14 at 2:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31117412
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
 |  Banyan Hill Publishing (Ad)
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
October 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prokidney-announces-eight-abstracts-selected-for-presentation-at-the-american-society-of-nephrology-s-kidney-week-2026-1036593328
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373819/0/en/prokidney-announces-eight-abstracts-selected-for-presentation-at-the-american-society-of-nephrology-s-kidney-week-2026.html
ProKidney consensus price target increased by 22.40% to MX$116.87
September 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/prokidney-consensus-price-target-increased-by-22-40-to-mx-116-87/ar-AA2ddQD8
See More ProKidney Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email.

About ProKidney

ProKidney (NASDAQ:PROK) (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease. The company’s approach is designed to support kidney function and potentially delay or reduce the need for dialysis or kidney transplantation in patients with progressive kidney disease.

Its lead product candidate, rilparencel, is an autologous renal cell therapy made from a patient’s own kidney cells. The cells are processed and administered back into the patient’s kidneys, where they are intended to promote the production of proteins and other factors associated with kidney health. ProKidney is evaluating rilparencel in clinical studies involving patients with diabetic kidney disease and other forms of chronic kidney disease.

ProKidney was founded in 2015 and became a publicly traded company in 2022 through a business combination with Social Capital Suvretta Holdings Corp. III. The company is headquartered in Winston-Salem, North Carolina, and its clinical development activities have primarily focused on patients and research sites in the United States.

View ProKidney Profile
Earnings Tools